St. Francis Medical: Staking Ground in Dynamic Stabilization
Spine, one of the device industry's hottest, most fertile segments, has a history of quick adoption and quick retrenchment (read spinal cages) and standards of care that are anything but gold standards. Perhaps the most interesting example of spine's ambivalent attitude toward technology is artificial discs. Artificial discs caught fire a couple of years ago in the US and promised to be the device industry's next blockbuster technology. But before the first-generation discs had even made it to market, spine surgeons-and the companies that develop new technology-were already onto the next big thing: dynamic stabilization devices, which fall somewhere between the motion-preserving qualities of disc replacement and the stabilization that cages offer. Dynamic stabilization devices are too new for their role in treating spine problems to be fully assessed, but a host of companies are already lining up. One of the first: St. Francis Medical Technologies, which after a difficult struggle with the FDA to get its device approved, is ready to take on the US market and test the potential of at least one category of dynamic stabilization devices: interspinous spacer devices.
By David Cassak
In most medical device segments, the promise of new technology lies in its obvious and straightforward efficacy: a new, clearly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.